Dr Konstantinos (Kostas) Stylianou Short CV

Education: Dr Stylianou received his M.D. degree from the Medical School of the University of Crete (UoC) in 1994 and his Ph.D. degree from the Division of Nephrology at the University of Crete in 2010.

Positions and clinical experience: He has been working in the field of clinical nephrology since 1999. He is an associate Professor of Nephrology at the Medical School of the University of Crete and director of the Nephrology Department at Heraklion University Hospital since 2020. The department provides facilities for acute and chronic haemodialysis (15000 sessions per year), peritoneal dialysis (40 patients), plasma exchange (coverage of Crete and South Aegean Islands), immunoadsorption and lipid-apheresis. The department runs 15 outpatient clinics per week (including a transplant clinic), a general nephrology ward with 20 beds and around 1800 admissions per year, and provides a wide range of invasive procedures. It also covers acute and emergency needs for all public and private dialysis units in Crete.
Dr Stylianou has worked as a nephrologist in the Royal Infirmary of Edinburgh and Queen Margaret Hospital in Scotland during the years 2004-2005.

Scientific interests: His current research aims to understanding the genetic basis of familial and chronic kidney disease of unknown aetiology as well as the study of kidney biopsies from patients with glomerulonephritis and inherited diseases with electron microscopy. One of his major clinical interests is the study of cardiorenal syndrome. His PhD thesis concerned the activation of PI3/AKT/mTOR pathway in lupus nephritis and the role of mTOR inhibitors.

Teaching record: Dr Stylianou is responsible for training medical students in the preclinical and clinical stages of studies in the UoC, registrars in renal medicine and postgraduate students in various universities in Greece. He also teaches physiology and pathophysiology in the international programme in medicine of the UoC. He has been a member of the educational committee of the Greek Society of Nephrology for nine years and has given several lectures in national or international congresses and advisory boards.

Scientific recognition: He is a reviewer for numerous international journals and an editor for the Journal of Clinical Medicine and Frontiers in Physiology.
He has served as an expert evaluator for the Hellenic Foundation for Research and Innovation (H.F.R.I.).
Dr Stylianou has organized 4 nephrology conferences in Greece, including the 24th National Congress of Nephrology and the European Vasculitis Society Educational congress in 2023.

Metrics: He has published 97 papers in international journals. He has received 2800 citations and has a h-index of 28.

Employment History

1) Consultant Nephrologist, Nephrology Department, Heraklion University Hospital (2005 up to 2020).
3) Locum Consultant, Renal Unit - Queen Margaret Hospital, Fife Scotland (2004-5).
4) Locum Staff Grade, Renal Unit - Royal Infirmary of Edinburgh (2004).
5) Specialist Registrar, Nephrology, University Hospital of Heraklion (1999-2003).
6) Registrar, Internal Medicine, Naval Hospital of Crete, (1999).
7) Registrar, Internal Medicine, University Hospital of Heraklion (1996-98).

Participation in current research projects
1. Project: Nutritional assessment and prevalence of protein-energy wasting in end stage renal disease patients. University of Crete, Medical School, Nephrology Lab and TUOC, Dietetics Department 2010-2024.
2. Collaboration on Alport syndrome and thin basement membrane nephropathy: In search for genetic modifiers. In collaboration with the University of Cyprus. 2018-2023.
3. European collaboration on LCAT deficiency treatment project with CER001 2023-2025
4. LCAT deficiency disorders: natural history and biomarkers identification. A multi-center international study (USA, Italy, Greece). 2023
5. INGENIUM Rare Neurogenetic Disease Initiative 2024: a multidisciplinary team focusing on specific rare disease subsets, enhancing diagnostic accuracy.

Participation in pharmaceutical research
He currently participates in 22 multicentre phase II and III RCTs, as a primary investigator or as a national leader (3)

Selected publications related to genetic kidney disorders and cardiorenal syndrome

1. Voskarides K, Demosthenous P, Stylianou K, et al. Epistatic role of the MYH9/APOL1 region on familial hematuria genes. **PLoS One. 2013**

2. Pieri M, Stefanou C, Zaravinos A, Erguler K, Stylianou K, et al. Evidence for Activation of the Unfolded Protein Response in Collagen IV Nephropathies. **J Am Soc Nephrol 2013**

3. Petrakis I, Mavroeidi V, Stylianou K, et al. Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis. **Amyloid 2013**.

4. Petrakis I, Mavroeidi V, Stylianou K, et al. Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amyloidosis: does the enviroment play a role. **Transgenic Res. 2013**

5. K Voskarides; C. Stephanou; M. Pieri; K. Stylianou; et al. A functional variant in NEPH3 gene confers high risk of renal failure in primary hematuric glomerulopathies. Evidence for predisposition to microalbuminuria in the general population. **PloS One. 2017**

6. L, Papagregoriou G, Hadjipanagi D, Demosthenous P, Voskarides K, Koutsofti C, Stylianou K, et al. Frequent COL4 mutations in familial microhematuria accompanied by later-onset Alport nephropathy due to focal segmental glomerulosclerosis. **Clin Genet. 2017**

7. Koulousios K, Stylianou K, Pateinakis P, et al. Fabry disease due to D313Y and novel GLA mutations. **BMJ Open 2017**

8. N. Fountoulakis, Dafnis, K. Stylianou. The P274S Mutation of Lecithin-Cholesterol Acyltransferase (LCAT) and Its Clinical Manifestations in a Large Kindred. **American Journal of Kidney Disease 2019**

9. Vitali C, Bajaj A, Nguyen C, Schnall J, Chen J, Stylianou K, Rader DJ, Cuchel M, A systematic review of the natural history and biomarkers of primary Lecithin: Cholesterol Acyltransferase (LCAT) deficiency, **Journal of Lipid Research (2022).**

10. Petrakis I, Drosataki E, Stylianou K. The p.Pro482Ala Variant in the CNNM2 Gene Causes Severe Hypomagnesemia Amenable to Treatment with Spironolactone. **Int J Mol Sci. 2022** Jun 30;23(13):7284.

11. Drosataki E, Stylianou K. Dent-2 disease with a Bartter-like phenotype caused by the Asp631Glu mutation in the OCRL gene. **BMC Nephrol. 2022** May 12;23(1):182.

12. Georgopoulou, T.; Petrakis, I.; Stylianou, K. Cardiorenal Syndrome: Challenges in Everyday Clinical Practice and Key Points towards a Better Management. **J. Clin. Med**. **2023**, 12, 4121. https://doi.org/ 10.3390/jcm12124121.

13. Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A, Vural A, Gok M, Yenicesu M, Daphnis E, Yilmaz MI. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. **Clin J Am Soc Nephrol**. **2012** Feb;7(2):207-15. doi: 10.2215/CJN.06840711.

14. Stylianou K, Petrakis I, Mavroeidi V, Stratakis S, Vardaki E, Perakis K, Stratigis S, Passam A, Papadogiorgaki E, Giannakakis K, Nakopoulou L, Daphnis E. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin. **Nephrol Dial Transplant**. **2011** Feb;26(2):498-508. doi: 10.1093/ndt/gfq496.

With Regards
Kostas Stylianou
Heraklion 14/02/2025